Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs TG Therapeutics Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $59.85 (market cap $77.37B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 9.4× TG Therapeutics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MDLZ | TGTX | |
|---|---|---|
Market Cap | $77.37B | $8.26B |
Sector | Consumer Staples | Health |
52-Week High | $70.75 | $59.06 |
52-Week Low | $51.51 | $26.39 |
Enterprise Value | $97.46B | $8.50B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $59.86, down 1.87% today but maintains a bullish technical signal with strong moving average support. The company reported Q1 2026 EPS of $0.67, beating expectations, and shows consistent revenue growth reaching $38.54B in 2025. Analyst consensus is strongly bullish with a $68.00 price target, representing 13.6% upside potential from current levels.
MDLZ offers stable dividend income and brand strength but faces margin compression risks from input cost inflation. The upcoming Q2 2026 earnings report on July 28, 2026 serves as the next major catalyst. While valuation multiples appear elevated, the company's market leadership and innovation pipeline support long-term growth prospects despite near-term profitability challenges.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
